Who are Celecoxib + Acetaminohen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexketoprofen Trometamol + Paracetamol, Celecoxi + Acetaminophen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/celecoxib-acetaminohen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Celecoxib + Acetaminohen — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Celecoxib + Acetaminohen (Celecoxib + Acetaminohen) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NSAID + analgesic combination. Area: Pain Management / Rheumatology.

phase 3 NSAID + analgesic combination COX-2 (celecoxib); prostaglandin synthesis pathway (acetaminophen) Pain Management / Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

Celecoxib + Acetaminohen (Celecoxib + Acetaminohen) — Laboratorios Silanes S.A. de C.V.. Celecoxib selectively inhibits COX-2 to reduce inflammation and pain, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Celecoxib + Acetaminohen TARGET	Celecoxib + Acetaminohen	Laboratorios Silanes S.A. de C.V.	phase 3	NSAID + analgesic combination	COX-2 (celecoxib); prostaglandin synthesis pathway (acetaminophen)
Dexketoprofen Trometamol + Paracetamol	Dexketoprofen Trometamol + Paracetamol	Yuzuncu Yil University	marketed	NSAID + analgesic combination	COX-1, COX-2 (dexketoprofen); central prostaglandin synthesis and pain pathways (paracetamol)
Celecoxi + Acetaminophen	Celecoxi + Acetaminophen	Laboratorios Silanes S.A. de C.V.	phase 3	NSAID + Analgesic combination (COX-2 selective inhibitor + acetaminophen)	COX-2 enzyme; prostaglandin synthesis pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NSAID + analgesic combination class)

Laboratorios Silanes S.A. de C.V. · 1 drug in this class
Yuzuncu Yil University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Celecoxib + Acetaminohen — Competitive Intelligence Brief. https://druglandscape.com/ci/celecoxib-acetaminohen. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab